Company / Free Cash Flow
Corcept Therapeutics Incorporated Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$141.8M
FY2025
5-year range
$126.5M / $196.1M
FY2021-FY2025
Trend
-27.7%
vs FY2024
Sector context
#40 of 194
Health Care
What the data says
Corcept Therapeutics Incorporated's free cash flow of $142M is higher than 79% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$28M in FY2016 to $196M in FY2024.
Based on SEC 10-K filings.
$142M in FY2025 with a 5-year CAGR of +4.2%. Top quartile in the Health Care sector.
Improved from $127M to $142M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- -
Sector benchmark
-69.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, free cash flow decreased 27.7% year-over-year.
- Ranks #40 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $141.8M | -27.7% |
| FY2024 | $196.1M | +55.0% |
| FY2023 | $126.5M | -16.0% |
| FY2022 | $150.7M | +11.6% |
| FY2021 | $135.0M | +17.0% |
| FY2020 | $115.4M | +90.6% |
| FY2019 | $60.5M | +232.6% |
| FY2018 | $18.2M | -69.9% |
| FY2017 | $60.5M | +319.7% |
| FY2016 | -$27.6M | -985.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026